Drugs / NYR-BI03
last change Aug 2026 re-read 3 minutes ago

NYR-BI03

Investigated by
Nyrada Pty Ltd

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06894862 Mar → Jul 2025 — Nyrada Pty Ltd Completed Met primary

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-08-05 Nyrada Pty Ltd Results CSANZ26 Conference Poster nyrada.com ↗
The poster presents preclinical data showing that Xolatryp® provided significant cardioprotection in two studies using a rat model of myocardial ischemia-reperfusion injury.
2026-06-03 Nyrada Pty Ltd Results Nyrada Successfully Completes Cardioprotection Pilot Study nyrada.com ↗
Preliminary biomarker data showed numerically lower mean cardiac troponin I, a clinically relevant marker of cardiac injury, in the 12 mg/kg/day and 36 mg/kg/day treatment groups relative to the doxorubicin plus vehicle control group.
2024-12-31 Nyrada Pty Ltd Regulatory NYR-BI03 Phase Ia Clinical Trial Update 2 nyrada.com ↗
Nyrada confirms that its Phase Ia first -in-healthy human volunteer clinical trial regulatory package has been submitted for Human Research Ethics Committee (HREC) review.

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NYR-BI03 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06894862 ↗
Route Intravenous “continuous intravenous infusion” NCT06894862 ↗